Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial
- Vermersch, P.
- Oreja-Guevara, C.
- Siva, A.
- Van Wijmeersch, B.
- Wiendl, H.
- Wuerfel, J.
- Buffels, R.
- Kadner, K.
- Kuenzel, T.
- Comi, G.
ISSN: 1468-1331, 1351-5101
Argitalpen urtea: 2022
Alea: 29
Zenbakia: 3
Orrialdeak: 790-801
Mota: Artikulua